Glenn Killingworth joins PCI as VP of Business Development

Will drive business growth at the Newburyport, MA, US-based firm

Glenn Killingworth has joined PCI Synthesis, a custom chemical manufacturer of new chemical entities (NCE), generic active pharmaceutical ingredients (APIs), complex pharmaceutical intermediates and other specialist products, as Vice President of Business Development.

In his new role, Killingworth will drive business growth through the development and implementation of PCI's sales and marketing strategy and building and leading business development teams to embrace new opportunities for PCI in current and new markets worldwide.

An organic chemistry specialist, Killingworth brings 25 years of experience working for specialist companies including Fisher Scientific, Peakdale Molecular, Almac Sciences, WuXi Apptec and Asymchem. He has spent the last decade in commercial and business development roles.

Killingworth will be based at the company's Newburyport, MA headquarters.

You may also like

Manufacturing

Seqens isopropanol plant expansion

The plant has almost been completed and is due to be finalised as planned by end of Q1 2022
Manufacturing

PCI Synthesis obtains DEA registration for controlled substance development and manufacturing

Certification expands the company's capabilities to handle cGMP development for schedule II, III, IV and V
Manufacturing

PCI Synthesis establishes a cGMP Advanced Polymer Development and Manufacturing Group

The team has experience with developing polymeric materials for implantable medical devices, drug delivery technologies, therapeutics, excipients and medical grade coatings
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Initiating change in drug development and manufacture

With R&D and production costs spiralling and the growing regulatory requirements biting into the profit margins of drug sales, the industry needs radical change to manufacturing models, argues Ed Price, President, PCI Synthesis
Manufacturing

PCI Synthesis earns top Life Science Leader awards for second year in a row
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

GDUFA – the promise and the reality

The introduction of GDUFA was meant to reduce a regulatory backlog and improve patient safety. Edward Price, President, PCI Synthesis, argues it has, in fact, had a more far-reaching impact
Manufacturing

WuXi AppTec peptide facility receives PMDA approval

The company's Changzhou oligonucleotide API manufacturing site was approved by Japan's Pharmaceuticals and Medical Devices Agency
Subscribe now